Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

• Status: Withdrawn
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Phosphodiesterase Inhibitors; Sildenafil Citrate

Criteria

Inclusion Criteria:Patients with primary and secondary pulmonary arterial hypertension

-

Exclusion Criteria:Unstable patients or patients with allergy to sildenafil